Literature DB >> 12111306

Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid.

Natalia Teleshova1, Mikhail Pashenkov, Yu-Min Huang, Mats Söderström, Pia Kivisäkk, Vasilios Kostulas, Mats Haglund, Hans Link.   

Abstract

A role for chemokines as mediators of Th1 cell recruitment to the central nervous system (CNS) is probable in MS. Therefore we studied expression of Th1-related CCR5 and CXCR3 chemokine receptors in patients with MS and controls. Patients with untreated MS had elevated percentages of CCR5 and CXCR3 expressing T cells vs. healthy controls (HC) in blood, and vs. other non-inflammatory neurological diseases (OND) patients in CSF. Such elevation was not found in MS patients examined during ongoing treatment with IFN-beta. Patients with optic neuritis (ON), a common first manifestation of MS, had elevated percentages of CXCR3 expressing T cells in blood compared with HC, and of CCR5 expressing T cells in CSF compared with OND patients. High chemokine receptor expression may be one prerequisite for Th1 cells to migrate to the CNS. Inhibition of chemokine receptor expression may constitute a potentially important therapeutic effect of IFN-beta.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111306     DOI: 10.1007/s00415-002-0699-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

2.  CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro.

Authors:  Eroboghene E Ubogu; Melissa K Callahan; Barbara H Tucky; Richard M Ransohoff
Journal:  Cell Immunol       Date:  2007-01-25       Impact factor: 4.868

3.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

4.  The Expression of CXCL10/CXCR3 and Effect of the Axis on the Function of T Lymphocyte Involved in Oral Lichen Planus.

Authors:  Jiaxiang Fang; Chen Wang; Chen Shen; Jing Shan; Xuewei Wang; Lin Liu; Yuan Fan
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

5.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

6.  Traffic of leukocytes and cytokine up-regulation in the central nervous system in sepsis.

Authors:  Clarissa M Comim; Márcia C Vilela; Larissa S Constantino; Fabrícia Petronilho; Franciele Vuolo; Norinne Lacerda-Queiroz; David H Rodrigues; João Luiz da Rocha; Antônio L Teixeira; João Quevedo; Felipe Dal-Pizzol
Journal:  Intensive Care Med       Date:  2011-02-25       Impact factor: 17.440

7.  Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis.

Authors:  Hideto Nakajima; Masakazu Sugino; Fumiharu Kimura; Toshiaki Hanafusa; Toshiyuki Ikemoto; Akira Shimizu
Journal:  Biomark Insights       Date:  2007-12-18

8.  Optic neuritis: chemokine receptor CXCR3 and its ligands.

Authors:  T L Sørensen; H Roed; F Sellebjerg
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

Review 9.  Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?

Authors:  Carine Savarin-Vuaillat; Richard M Ransohoff
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis.

Authors:  Stephan Segerer; Bernhard Banas; Markus Wörnle; Holger Schmid; Clemens D Cohen; Matthias Kretzler; Matthias Mack; Eva Kiss; Peter J Nelson; Detlef Schlöndorff; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.